CD4+ effector and memory cell populations protect against Cryptosporidium parvum infection

CD4+ effector and memory cell populations protect against Cryptosporidium parvum infection
复制标题

DOI:
10.1016/j.micinf.2013.04.009
复制
发表时间:
2013-07-01
影响因子:
5.8
通讯作者:
Mead, Jan R.
Mead, Jan R.
中科院分区:
医学3区
文献类型:
--
作者:
McNair, Nina N.;Mead, Jan R.

文献摘要

被引文献

相似文献

微小隐孢子虫是一种原生动物寄生虫,感染小肠上皮细胞,导致人类肠道疾病。虽然已知T细胞在抵抗和从感染中恢复中是重要的,但是很少有关于感染后表面效应物和记忆标志物的表型表达的特征。我们使用急性感染模型(C57 BL/6白细胞介素-12 p40),该模型对再感染产生长期抗性,以表征不同效应细胞和记忆细胞的表达。使用流式细胞术,我们发现感染后产生的异质群体,包括CD62L(高)中央记忆T细胞(T-CM)和CD62L(低)效应记忆T细胞(T-EM),能够产生Th 1型效应细胞因子,IFN-γ。CD4(+)和CD8(+)T-CM和T-EM群体在没有感染的情况下持续存在(感染后60天)。此外,将CD62 L(低)CD4 + TEm或CD62(高)CD4 + T-CM转移到幼稚受体中导致保护性应答。总之,这些研究表明,不同的亚群的效应和记忆CD4 + T细胞感染后,与C。parvum,并介导保护性免疫再挑战。由Elsevier Masson SAS代表巴斯德研究所发布。
Cryptosporidium parvum is a protozoan parasite that infects the epithelial cells of the small intestine causing diarrheal illness in humans. While T cells are known to be important in resistance and recovery from infection, little has been characterized as to the phenotypic expression of surface effector and memory markers after infection. We used an acute model of infection (C57BL/6 interleukin-12p40), which develops long-standing resistance to re-infection, to characterize expression of different effector and memory cells. Using flow cytometry, we found that heterogeneous populations were generated after infection, consisting of both CD62L(high) central memory T cells (T-CM) and CD62L(low) effector memory T cells (T-EM) that were competent to produce the Th type 1 effector cytolcine, IFN-gamma. Both CD4(+) and CD8(+) T-CM and T-EM populations persisted in the absence of infection (up to 60 days post-infection). Additionally, transfer of either CD62L(low)CD4+ TEm or CD62(high)CD4+ T-CM into naive recipients resulted in a protective response. Taken together, these studies show that distinct subsets of effector and memory CD4+ T cells develop after infection with C. parvum, and mediate protective immunity to re-challenge. Published by Elsevier Masson SAS on behalf of Institut Pasteur.